International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Int J Oncol 56: [Related article:] 1499-1508, 2020; DOI: 10.3892/ijo.2020.5015
Following the publication of the above paper, an interested reader has contacted the Editorial Office to raise a couple of concerns regarding the description of experimental details in the paper. First, in the Materials and methods section, it was stated that the miRNA targets were predicted using miRWalk2 and TargetScan; however, in the Discussion section, ZEB1 and ZEB2 were described only as potential target genes identified by bioinformatics, and the authors explicitly stated that further studies would be required to elucidate how miR-500a-5p modulates ZEB1 and/or ZEB2. It was not possible to identify an experiment in the main article that directly tested miR-500a-5p binding to, or functional dependence on, a candidate target; therefore, the authors should clarify whether a direct target of miR-500a-5p was experimentally validated.
Secondly, in the Materials and methods section, it was also stated that cells transfected with the miR-500a-5p inhibitor were treated with 80 μM emodin for 48 h. A 0-80 μM emodin dose series for 48 h was also used for the western blot experiments, and Fig. 3E employed a Matrigel assay to conclude that emodin suppresses the increased invasion associated with the miR-500a-5p inhibitor; however, it was not possible to identify a matched measurement of cell viability, apoptosis, proliferation, attachment, or viable cell number at 80 μM emodin for 48 h. The authors could have provided the viability and cell-number data for each experimental condition in Fig. 3, and should clarify whether emodin remained present during the Transwell assay, and also whether equal numbers of viable cells were seeded after treatment.
The authors have been contacted by the Editorial Office to offer an explanation for these possible omissions in the presentation of the data in this paper, and we are awaiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of these potential problems while the Editorial Office continues to investigate this matter further.